Jonathan Lavian is a Dermatology physician affiliated with Hofstra University. OpenAlex indexes 17 publications with 732 citations (h-index 8).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2127 E Baseline Rd Ste 104
Tempe, AZ 852831537
Telephone
804-556-0446Provider last certified this registry record 20 Apr 2025.
Industry payments
25 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- UCB, Inc.Program year202515 payments
- Incyte CorporationProgram year202512 payments
- ABBVIE INC.Program year202513 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
37.5%Azole Antifungal15%Ketoconazole100%Part D≥82 patientsTetracycline-class Drug14.8%Doxycycline Monohydrate93%Doxycycline Hyclate7%Part D≥114 patients+ 3 more classes in this area
Dermatology
24.4%Corticosteroid14%Triamcinolone Acetonide79%Triamcinolone acetonide11%Fluocinolone Acetonide10%Part D + Part B<11 patientsalpha-Hydroxy Acid5%Ammonium Lactate100%Part D≥39 patients+ 2 more classes in this area
Sensory organs
15.2%Corticosteroid15.2%Clobetasol Propionate79%Hydrocortisone21%Part D≥81 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Tofacitinib therapy for alopecia areata is not associated with adverse events during COVID-19 infection
Journal of the American Academy of Dermatology
2022 - 33432 Prevalence estimates for alopecia areata in the United States
Journal of the American Academy of Dermatology
2022 - Incidence estimates for lichen planopilaris and frontal fibrosing alopecia in a New York City health care system
Dermatology Online Journal
2021 - 25580 Prevalence estimates for lichen planopilaris and frontal fibrosing alopecia in the United States
Journal of the American Academy of Dermatology
2021 - Prevalence estimates for lichen planopilaris and frontal fibrosing alopecia in a New York City health care system
Journal of the American Academy of Dermatology
2020
Similar KOLs
Other experts from the same institution or the same specialty.
Michael Iannuzzi, MD
Hofstra University
Jacqueline Barrientos, MD
Hofstra University
Sujana Chandrasekhar, MD
Hofstra University
Jamie Green, MD
Hofstra University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”